|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016360,
umls-concept:C0017337,
umls-concept:C0033262,
umls-concept:C0038661,
umls-concept:C0067685,
umls-concept:C0077844,
umls-concept:C0086222,
umls-concept:C0086860,
umls-concept:C0205369,
umls-concept:C0334227,
umls-concept:C0376358,
umls-concept:C0599894,
umls-concept:C1310550,
umls-concept:C1333570,
umls-concept:C1533691,
umls-concept:C1705733,
umls-concept:C2587213
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-5-12
|
|
pubmed:abstractText |
This study was designed to investigate the prostate cancer-specific tumoricidal effect of the suicide gene, Escherichia coli uracil phosphoribosyltransferase (UPRT), driven by the human prostate-specific membrane antigen promoter/enhancer (PSMA(E/P)) in vitro. When transfected with PSMA(E/P)-EGFP (enhanced green fluorescence protein) (a plasmid construct with the green fluorescence protein gene driven by the PSMA(E/P)), only the androgen-responsive and PSMA-positive prostate cancer cell line, LNCaP, expressed GFP, indicating the specificity of the PSMA(E/P) activity in androgen-sensitive and PSMA-positive prostate cancer cells. Taking advantage of this prostate cancer-specific property of PSMA(E/P), we successfully introduced bacterial UPRT into LNCaP cells where the tumoricidal effect of 5-fluorouracil (5-FU) was significantly increased when compared with the cells without the exogenous UPRT. We conclude that the efficacy of 5-FU-based chemotherapy in prostate cancers can be significantly improved by targeted expression of the suicide gene UPRT under the control of PSMA(E/P).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1476-5608
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
166-71
|
|
pubmed:meshHeading |
pubmed-meshheading:18626508-Antigens, Surface,
pubmed-meshheading:18626508-Antineoplastic Agents,
pubmed-meshheading:18626508-Cell Line, Tumor,
pubmed-meshheading:18626508-Enhancer Elements, Genetic,
pubmed-meshheading:18626508-Escherichia coli,
pubmed-meshheading:18626508-Flow Cytometry,
pubmed-meshheading:18626508-Fluorouracil,
pubmed-meshheading:18626508-Gene Therapy,
pubmed-meshheading:18626508-Genes, Transgenic, Suicide,
pubmed-meshheading:18626508-Genetic Vectors,
pubmed-meshheading:18626508-Glutamate Carboxypeptidase II,
pubmed-meshheading:18626508-Green Fluorescent Proteins,
pubmed-meshheading:18626508-Humans,
pubmed-meshheading:18626508-Male,
pubmed-meshheading:18626508-Pentosyltransferases,
pubmed-meshheading:18626508-Promoter Regions, Genetic,
pubmed-meshheading:18626508-Prostatic Neoplasms,
pubmed-meshheading:18626508-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18626508-Transfection
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
|
|
pubmed:affiliation |
Department of Urology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
